GLP-1 Peptides: Semaglutide, Tirzepatide, Retatrutide & How They Work
Medically reviewed by Medical Advisory Board Last reviewed 2026-08-10
The complete guide to GLP-1 receptor agonist peptides — mechanisms, drug comparisons, side effects, and what's coming next
GLP-1 (glucagon-like peptide-1) is a naturally occurring gut peptide that regulates appetite, blood sugar, and gastric emptying. GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and the in-development retatrutide — are peptide-based drugs producing 15–24% average weight loss in clinical trials. This guide covers how they work, compares current options, and explains what's coming next.
GLP-1 receptor agonists are arguably the most transformative class of drugs developed in the past decade. Semaglutide alone generated more than $13 billion in revenue in 2023, driven by its unprecedented efficacy in both diabetes management and weight loss. These peptide-based drugs are small protein chains that mimic the natural gut hormone GLP-1.
After you eat, L-cells in the intestinal wall secrete GLP-1. Its natural half-life is just 1 to 2 minutes, but pharmaceutical versions are engineered through chemical modifications to last days to weeks. Understanding what GLP-1 does naturally helps explain the drug effects: it suppresses appetite, slows digestion, stimulates insulin release in response to blood glucose, and reduces glucagon, the counter-regulatory hormone that raises blood sugar.
Partner · Opt Health
Want peptides prescribed and monitored properly?
If you're considering peptide therapy, the difference between a clinical program and a gray-market vial is supervision. Opt Health prescribes peptides through licensed physicians with baseline labs and follow-up testing.
See Opt Health's peptide program →How GLP-1 Peptides Work
GLP-1 receptors are found in the pancreas, brain (hypothalamus, brainstem), stomach, heart, kidneys, and other tissues. Activating these receptors produces multiple coordinated effects:
- Appetite suppression (hypothalamus): GLP-1 acts directly on hunger centers in the brain to reduce "food noise" — the persistent mental preoccupation with eating that drives overconsumption. Clinical trial participants frequently describe this as the most significant subjective effect.
- Slowed gastric emptying: GLP-1 delays how fast food moves from the stomach to the small intestine, extending satiety and blunting post-meal glucose spikes.
- Glucose-dependent insulin release (pancreas): GLP-1 stimulates insulin secretion only when blood glucose is elevated, eliminating hypoglycemia risk (unlike sulfonylureas).
- Glucagon suppression: Reduces the liver's glucose output by suppressing glucagon, further stabilizing blood sugar.
- Cardiovascular protection: GLP-1 receptors in the heart and vessels produce anti-inflammatory effects. The SELECT trial showed semaglutide reduced major cardiac events by 20% in non-diabetic individuals with existing cardiovascular disease.
GLP-1 Drug Comparison
| Drug | Brand Names | Target | Avg. Weight Loss | Frequency | Status |
|---|---|---|---|---|---|
| Semaglutide | Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) | GLP-1 | 14.9% (STEP 1) | Weekly injection | FDA approved |
| Tirzepatide | Mounjaro (diabetes), Zepbound (obesity) | GIP + GLP-1 (dual) | 22.5% (SURMOUNT-1) | Weekly injection | FDA approved |
| Retatrutide | LY3437943 (Eli Lilly) | GIP + GLP-1 + glucagon (triple) | 24.2% at 48 wks (Phase II) | Weekly injection | Phase III trials |
| Orforglipron | Eli Lilly oral GLP-1 | GLP-1 (non-peptide) | ~15% (Phase II) | Daily oral pill | Phase III trials |
| Cagrilintide + sema | CagriSema | GLP-1 + amylin | ~22.7% (Phase III) | Weekly injection | Phase III trials |
| Liraglutide | Saxenda (obesity), Victoza (diabetes) | GLP-1 | ~8% (SCALE trial) | Daily injection | FDA approved (older) |
Semaglutide vs. Tirzepatide: Which to Choose
Both are effective — tirzepatide produces roughly 50% more weight loss on average. The key differences:
- Efficacy: Tirzepatide's dual GIP/GLP-1 mechanism appears synergistic. GIP receptors are expressed in fat cells directly, adding a fat-mobilizing effect that pure GLP-1 agonists don't have. Average weight loss is significantly higher.
- Side effects: Similar GI side effect profiles (nausea, diarrhea, constipation during titration). Some clinicians report tirzepatide causes slightly less nausea, possibly because GIP receptor activation partially counteracts GLP-1's nausea-inducing effects at the brainstem.
- Cost: Similar list price (~$1,000/month without insurance). Coverage varies significantly.
- Availability: Both have been subject to supply shortages and compounding pharmacy access issues. Check current status with your prescriber.
Comparing specific brands or alternatives? See Ozempic vs Wegovy (same drug, different use), Ozempic vs metformin, berberine vs Ozempic, and the head-to-head drug comparison: Ozempic vs Mounjaro or the obesity-approval showdown at Wegovy vs Zepbound.
What's Coming: The Next Generation
Retatrutide (Eli Lilly's triple agonist) showed 24.2% average weight loss at 48 weeks in Phase II — a figure previously seen only with bariatric surgery. Phase III data is expected 2025–2026. If confirmed, it may become the highest-efficacy pharmacological weight-loss option available without surgery.
Oral non-peptide GLP-1 agonists (orforglipron, danuglipron) are in Phase III and could dramatically expand access — eliminating the injection requirement that remains a barrier for some patients. These are small molecules, not peptides, but they activate the same GLP-1 receptor.
Frequently Asked Questions
What is a GLP-1 peptide?
GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone released after eating. It regulates appetite, blood sugar, and digestion. Pharmaceutical GLP-1 receptor agonists (semaglutide, tirzepatide) are synthetic peptide analogs engineered to last much longer than natural GLP-1 (days vs. minutes). They're among the most effective weight-loss medications ever developed.
Is semaglutide a peptide?
Yes. Semaglutide is a synthetic peptide — a modified version of the natural GLP-1 hormone. It consists of 31 amino acids (the same as natural GLP-1) with modifications that extend its half-life from minutes to approximately 1 week. This makes it suitable for once-weekly injection.
What's the difference between GLP-1 and GIP?
GLP-1 (glucagon-like peptide-1) primarily suppresses appetite, slows gastric emptying, and stimulates insulin release. GIP (glucose-dependent insulinotropic polypeptide) also stimulates insulin release but additionally acts on fat cells and may modulate GLP-1's nausea effects at the brainstem. Tirzepatide targets both receptors simultaneously, which appears to produce greater weight loss than GLP-1 agonism alone.
Can I get GLP-1 peptides without a prescription?
No. FDA-approved GLP-1 peptides (semaglutide, tirzepatide) require a prescription. During the drug shortage period (2022–2024), compounding pharmacies were permitted to produce compounded semaglutide and tirzepatide, but this access has been restricted as supplies normalized. Buying "research chemical" versions of these peptides from online vendors is both illegal and dangerous — the quality and dosing of unlicensed products cannot be verified. A separate, prescription-based practice, taking an approved GLP-1 drug at a below-label dose, is covered in our GLP-1 microdosing guide, which explains why no clinical trial has established a safe or effective protocol for that either.
Are GLP-1 drugs a longevity or anti-aging treatment?
No — semaglutide and tirzepatide are FDA-approved for type 2 diabetes and/or chronic weight management, not as anti-aging or longevity therapies, and no drug in this class carries an anti-aging indication. That said, the SELECT trial's cardiovascular risk reduction (noted above) has researchers actively studying whether GLP-1 drugs have broader healthy-aging benefits beyond their approved uses, since obesity and insulin resistance are themselves risk factors tracked in longevity research. It's an active research question, not an established use — see our NAD+ and longevity guide for how the broader healthy-aging field separates proven interventions from promising-but-unproven ones.
Do GLP-1 weight-loss patches actually work?
No FDA-approved GLP-1 patch exists, and there's no published efficacy data supporting one. GLP-1 analogs are peptides — relatively large molecules that don't meaningfully cross intact skin through passive transdermal delivery, which is exactly why every FDA-approved GLP-1 drug is either injectable or, for oral semaglutide, a tablet built with a specific absorption-enhancer technology rather than a simple pill. A patch claiming to deliver a GLP-1 peptide through the skin is making a pharmacologically implausible claim; treat such products with the same skepticism as any unregulated 'research chemical' vendor — see the prescription-only FAQ above for why that matters.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Want peptide therapy handled by a physician who works from your labs? See how Opt Health does it →
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Reading
-
IGF-1 LR3: Mechanism, Risks, and What the Research Actually Shows
IGF-1 LR3 mechanism, hyperplasia use case, risk profile, and how it compares to GH secretagogues.